Lai Xingjian, Xia Yu, Zhang Bo, Li Jianchu, Jiang Yuxin
Department of Ultrasound, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.
Oncotarget. 2017 Jun 27;8(37):62414-62424. doi: 10.18632/oncotarget.18620. eCollection 2017 Sep 22.
It remains inconclusive whether Hashimoto's thyroiditis (HT) predisposes patients to the development of papillary thyroid carcinoma (PTC). We conducted a meta-analysis of the available data to address this question.
Twenty-seven eligible studies were selected, including 18 archival thyroidectomy studies, 6 fine-needle aspiration (FNA) studies, and 3 selective FNA or thyroidectomy studies. A total of 76,281 patients, including 12,476 cases of thyroid cancer, were included in these studies. The mean rate of PTC among patients with HT ranged from 1.12% (selective FNA or thyroidectomy studies) to 40.11% (thyroidectomy studies). All three types of studies supported the correlation between HT and PTC. The overall pooled odds ratio (OR) of the PTC risk for HT (HT versus non-HT) was 2.12 (95% confidence interval [CI]: 1.78-2.52).
We searched all relevant published studies using the citation databases PubMed and Embase. The ORs and corresponding 95% CIs were calculated by the random-effects model for the association between HT and PTC.
Our meta-analysis confirmed that HT predisposed patients to the development of PTC.
桥本甲状腺炎（HT）是否使患者易患甲状腺乳头状癌（PTC）仍尚无定论。我们对现有数据进行了荟萃分析以解决这个问题。
共纳入27项符合条件的研究，包括18项存档甲状腺切除术研究、6项细针穿刺（FNA）研究以及3项选择性FNA或甲状腺切除术研究。这些研究共纳入76,281例患者，其中包括12,476例甲状腺癌病例。HT患者中PTC的平均发生率从1.12%（选择性FNA或甲状腺切除术研究）到40.11%（甲状腺切除术研究）不等。所有三种类型的研究均支持HT与PTC之间的相关性。HT发生PTC风险的总体合并比值比（OR）为2.12（95%置信区间[CI]：1.78 - 2.52）。
我们使用文献数据库PubMed和Embase检索了所有相关的已发表研究。采用随机效应模型计算HT与PTC之间关联的OR值及相应的95%CI。
我们的荟萃分析证实，HT使患者易患PTC。
